DJIA 17,067.56 -30.89 -0.18%
NASDAQ 4,598.19 17.92 0.39%
S&P 500 2,002.28 -1.09 -0.05%
market minute promo

Synageva BioPharma (NASDAQ: GEVA)

69.61 -2.56 (-3.55%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

GEVA $69.61 -3.55%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $72.54
Previous Close $72.17
Daily Range $69.39 - $73.54
52-Week Range $44.54 - $119.42
Market Cap $2.3B
P/E Ratio -15.23
Dividend (Yield) $0.00 (0.0%)
Volume 307,501
Average Daily Volume 239,062
Current FY EPS -$6.21

Sector

Healthcare

Industry

Drugs

Synageva BioPharma (GEVA) Description

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of a new class of antiviral drug treatments called fusion inhibitors. Website: http://www.synageva.com/

News & Commentary Rss Feed

5 of Last Week's Biggest Losers

These five stocks suffered double-digit percentage declines last week.

Synageva Slips on Wider-than-Expected Q2 Loss - Analyst Blog

Thursday's ETF Movers: BSCF, XBI

Sector Update: Health Care

Sector Update: Health Care Stocks Following Broader Markets Highers; GlycoMimetics Jumps More Than 1

Sector Update: Health Care Stocks Following Broader Markets Highers; GlycoMimetics Jumps More Than 10% After Naming Cancer-Specialist to Board

3 Stocks Crushed by the Market This Week

No pops and sizzles for these stocks. Just drops and fizzles.

Synageva Shares Tumble Amid Positive Phase 3 Data, A Director's 75% Gain & Analyst Concerns

Synageva's Sebelipase Alfa Meets Primary Endpoint in ARISE - Analyst Blog

Synageva BioPharma Reports Phase 3 Study Meets Primary Endpoint And Six Secondary Endpoints Across M

Synageva BioPharma Reports Phase 3 Study Meets Primary Endpoint And Six Secondary Endpoints Across Multiple Disease-Related Abnormalities

GEVA: Insiders Vs. Shorts

See More GEVA News...

GEVA's Top Competitors

GEVA $69.61 (-3.55%)
Current stock: GEVA
AMGN $137.96 (-1.02%)
Current stock: AMGN
GILD $109.36 (1.67%)
Current stock: GILD
BIIB $342.68 (-0.10%)
Current stock: BIIB